title: Lectin-histochemical detection of degenerative glycoconjugate deposits in human brain.
abstract: Several lectins were used to study the localization of glycoconjugates in brain of elderly people and patients with Alzheimer type dementia (ATD) and Down's syndrome (DS). Five kinds of degenerated or deposited materials stained clearly by lectins specific to GalNAC, Gal, Fuc, and/or Man were recognized much in ATD and DS, less in elderly peoples, in addition to the binding of the lectins to neurons. (i) Round shape deposits called corpora amylacea (CA) which consisted of various sizes of round material, existed mainly on the surface of cerebral cortex and some in white matter of the brain. They were colored by Alcian blue (AB), Aldehyde fucsin (AF) and periodic acid shiff (PAS) and weakly by Hematoxylin (H), but not by Eosin (B). They showed clear reactivity with lectins specific to GalNAC, Gal, Fuc and Gal-GalNAC. (ii) Amorphous and variform amyloid deposits existed around blood vessels in the white matter were stained by thioflavin and lectins specific to GalNAC, Gal and Fuc, but not with Man specific lectins and PAS, AB, AF and HE. (iii) Another kind of amyloid deposits which showed a similar characteristic to the previous one and were recognized mainly in white matter and independent blood vessels. These deposits were stained by thioflavin but not by PAS, AB, AF and HE and showed good reactivity with lectins specific to GalNAC, Gal, Fuc, Gal-GalNAC, Gal-GIcNAc and Man. The reactivity with lectins specific to Gal, Fuc, and Man was seen in senile plaques (iv) and neurofibrillary tangles (v). Although at present we are unable to explain the origin of these deposits, it is clear from this study that the glycoconjugates form an integral part of the degeneration in the brain. The lectin staining with GS-I is useful in the forensic pathology to diagnose brain disorders at postmortem examination, since these lectin were able to detect five types of degeneration changes and/or deposits.
authors.affiliation: Department of Legal Medicine, Shiga University of Medical Science, Setatsukinowa-cho, Ohtsu 520-2192, Shiga, Japan. akiyoshi@belle.shiga-med.ac.jp
authors.forename: A
authors.initials: A
authors.lastname: Nishimura
authors.forename: S
authors.initials: S
authors.lastname: Sawada
authors.forename: I
authors.initials: I
authors.lastname: Ushiyama
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Nakagawa
authors.forename: A
authors.initials: A
authors.lastname: Tanegashima
authors.forename: K
authors.initials: K
authors.lastname: Nishi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000473:pathology*; D000544:Alzheimer Disease / Q000473:pathology*; D001344:Autopsy / Q000379:methods*; D001923:Brain Chemistry; D016022:Case-Control Studies; D004314:Down Syndrome / Q000473:pathology*; D005260:Female; D006001:Glycoconjugates / Q000032:analysis* / Q000145:classification; D006651:Histocytochemistry / Q000379:methods*; D006801:Humans; D037102:Lectins; D008297:Male; D008875:Middle Aged
chemical_list: D006001:Glycoconjugates; D037102:Lectins